Teva and NATCO Pharma launch additional strengths for generic Revlimid

Teva Pharmaceuticals and NATCO Pharma announced the launch of additional strengths for the generic version of Revlimid, lenalidomide capsules, in 2.5 mg, and 20 mg strengths, in the United States. The companies have launched four other strengths of the product in March 2022 in the US market. With today’s launch the companies made available all the strengths of lenalidomide in the US market. Teva‘s lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment. Please see the below "What are lenalidomide capsules?" section for more information. "The launch of additional strengths for the generic version of Revlimid in the U.S. enhances access to an important treatment option for patients, and further demonstrates Teva’s commitment to making generic drugs available to the patients who need them," said Christine Baeder, SVP, Chief Operating Officer, US Generics and Biosimilars, at Teva USA. With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the U.S. Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product. Revlimid had annual sales of $2.9B as of January according to IQVIA data.